Noble Financial Issues Negative Forecast for UNCY Earnings

Unicycive Therapeutics, Inc. (NASDAQ:UNCY) – Investment analysts at Noble Financial decreased their Q2 2027 earnings per share (EPS) estimates for shares of Unicycive Therapeutics in a report issued on Thursday, August 13th. Noble Financial analyst R. Leboyer now expects that the company will earn $0.75 per share for the quarter, down from their prior forecast of $0.91. The consensus estimate for Unicycive Therapeutics’ current full-year earnings is ($1.49) per share. Noble Financial also issued estimates for Unicycive Therapeutics’ Q3 2027 earnings at $1.06 EPS and Q4 2027 earnings at $1.24 EPS.

Unicycive Therapeutics (NASDAQ:UNCY) last posted its quarterly earnings results on Wednesday, August 12th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.47) by $0.41.

UNCY has been the subject of a number of other research reports. B. Riley Financial reiterated a “buy” rating and issued a $20.00 target price (down from $22.00) on shares of Unicycive Therapeutics in a research report on Wednesday. HC Wainwright lowered their price target on shares of Unicycive Therapeutics from $22.00 to $15.00 and set a “buy” rating on the stock in a report on Tuesday, June 30th. Weiss Ratings raised shares of Unicycive Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, June 9th. Zacks Research lowered Unicycive Therapeutics from a “hold” rating to a “strong sell” rating in a report on Tuesday, July 21st. Finally, Benchmark reduced their price objective on Unicycive Therapeutics from $18.00 to $13.00 and set a “speculative buy” rating for the company in a research report on Wednesday, July 1st. Five analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, Unicycive Therapeutics has a consensus rating of “Hold” and an average target price of $18.25.

Unicycive Therapeutics Stock Performance

Shares of UNCY opened at $5.40 on Friday. The company has a market capitalization of $147.91 million, a PE ratio of -3.09 and a beta of 1.79. The company’s 50 day moving average price is $5.97 and its 200 day moving average price is $6.65. Unicycive Therapeutics has a 52 week low of $3.71 and a 52 week high of $8.74.

Institutional Trading of Unicycive Therapeutics

Large investors have recently modified their holdings of the company. Lazard Asset Management LLC acquired a new position in Unicycive Therapeutics in the 2nd quarter valued at $55,000. JPMorgan Chase & Co. boosted its holdings in Unicycive Therapeutics by 11,698.4% during the second quarter. JPMorgan Chase & Co. now owns 21,709 shares of the company’s stock valued at $104,000 after acquiring an additional 21,525 shares during the period. Renaissance Technologies LLC bought a new stake in Unicycive Therapeutics during the first quarter valued at about $161,000. Citadel Advisors LLC acquired a new stake in shares of Unicycive Therapeutics in the third quarter valued at about $182,000. Finally, Bank of America Corp DE grew its position in shares of Unicycive Therapeutics by 19,327.6% in the first quarter. Bank of America Corp DE now owns 29,530 shares of the company’s stock valued at $194,000 after purchasing an additional 29,378 shares during the last quarter. 40.42% of the stock is owned by institutional investors.

About Unicycive Therapeutics

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.